Hot Investor Mandate: China Investment Firm with Big Pharma Connections Invests in Global Life Science Companies from Angel to Series B Rounds

20 Feb

An investment firm headquartered in China manages three venture capital funds in RMB with a total of 1,400 MM RMB (~200MM USD); the firm is still raising a fund in U.S. dollars of 50MM~100MM USD, with the confirmed limited partners from well-known Chinese big pharma.

The firm has 24 portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, the firm selects 10-15 companies to invest, and each investment ranges from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the follow-on rounds of those selected companies to help them grow.

The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm has no specific requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: